Terminé

Cerebrovascular Involvement in Sickle Cell Disease - Comprehensive Sickle Cell Center

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est collecté

Collecte de données

Qui peut participer

Anémie+13

+ Anémie hémolytique

+ Anémie hémolytique congénitale

Jusqu'à 100 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Observationnel
Date de début : janvier 1988
Voir le détail du protocole

Résumé

Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 16 mars 2016
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 1 janvier 1988

Date à laquelle le premier participant a commencé l'étude.

BACKGROUND: Stroke represents a focal brain insult whereas chronic encephalopathy represents a diffuse brain disturbance involving cognition and memory. The predisposition to stroke and the potential for dementia were increasingly apparent from our studies and the work of other investigators in sickle cell disease. The ontogeny of these two processes required further study before the mechanisms could be clearly articulated; and a coordinated assessment of cerebrovascular perfusion was needed to decipher the relationship between focal perfusion deficits and occlusion of large and small cerebral vessels. 150 subjects were enrolled in these studies. Improved understanding of the mechanisms underlying these two devastating neurological complications of SCD should result in prevention or effective treatment. DESIGN NARRATIVE: Three hypotheses were tested: (1) clinically-silent cranial magnetic resonance imaging (MRI) abnormalities represented the minimal expression of the neurovascular diathesis, and were the harbingers of clinically-overt strokes (study A); (2) sickle cell disease patients who developed cerebral infarctions had a predisposing risk factor(s) that contributed to this neurological complication (study B); and (3) sickle cell disease patients developed a chronic encephalopathy and dementia that was independent of the neurovascular diathesis (study C). Study A was a prospective evaluation of 50 SCD children aged 6 to 12 years attempting to identify a subgroup of patients at risk for the development of a clinically-apparent stroke. These patients were evaluated clinically, and underwent MRI scan, magnetic resonance angiography (MRA), and single photon emission computerized tomography (SPECT). Study B represented two studies designed to analyze risk factors for stroke. The first study was a retrospective case-control analysis of 25 young adults who suffered one or more strokes. These patients were age-matched to an SCD control group which had been clinically free of strokes and had MRI, MRA, and SPECT studies. The second study represented a prospective case-control analysis of children who were being followed in study A. Study C represented a prospective study of 50 SCD children, and 50 age-matched siblings or closest available relatives. Annual neurological examinations and neuropsychological evaluations were performed searching for evidence of chronic encephalopathy and dementia. The longitudinal study design was necessary to dissect out the subtle variables that contributed to the cognitive deficits. The study was renewed in FY 1998 to continue through FY 2004. Note: Darryl DeVivo was PI on Subproject which began in FY 1988 as a competing renewal. The total grant began several years prior to that. Dollars for the subproject were estimated at 10% of the total funds awarded each year. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

NCT00005326
Sponsor principalNational Heart, Lung, and Blood Institute (NHLBI)
Dernière mise à jour : 16 mars 2016
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.

Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Homme

Le sexe biologique des participants éligibles à s'inscrire.

Jusqu'à 100 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

AnémieAnémie hémolytiqueAnémie hémolytique congénitaleMaladies du cerveauMaladies CardiovasculairesMaladies du système nerveux centralTroubles cérébro-vasculairesMaladies hématologiques et lymphatiquesHémoglobinopathiesMaladies et anomalies congénitales, héréditaires et néonatalesMaladies du système nerveuxMaladies vasculairesMaladies Génétiques CongénitalesAnémie à cellules falciformesMaladies HématologiquesAccident Vasculaire Cérébral

Critères

No eligibility criteria

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.
Cette étude n'a pas de données de localisationAjoutez cette étude à vos favoris pour savoir quand les données de localisation seront disponibles.
TerminéAucun centre d'étude